Journal of Blood & Lymph

Unveiling ST2 as a Novel Immune Checkpoint in AML

Abstract

Hua Jiang and Sophie Paczesny*

While anti-PD1/PDL1 immune checkpoint blockade has shown promising clinical success in solid tumors [1,2] its effectiveness in Acute Myeloid Leukemia (AML) remains limited, AML is considered an immunologically 'cold' tumor [3] despite evidence of CD8+ T cell exhaustion in patients. Although advances in targeted therapies and supportive care have improved survival outcomes in AML, the pace of therapeutic immune innovation in AML has notably lagged behind that observed in acute B-cell and T-cell leukemias, lymphomas and multiple myeloma over the past three decades [4,5].